THOMAS F. MCINERNEY
(212) 415-9215
December 7, 1998
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Attn: Filing Desk
Re: Enzon, Inc.- Current Report on Form 8-K
Ladies and Gentlemen:
On behalf of our client Enzon, Inc. (the "Company"), we are transmitting
electronically the Company's Current Report on Form 8-K (the "Form 8-K") dated
November 20, 1998.
Please note that the Form 8-K filed herewith contains a conformed signature
and that an original, manual signature will be retained in the Company's records
for five (5) years.
Very truly yours,
/s/THOMAS F. MCINERNEY
Thomas F. McInerney
cc: Kenneth J. Zuerblis
<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 20, 1998
ENZON, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-12957 22-2372868
(State or other jurisdiction (Commission (IRS EMPLOYER
or incorporation) File Number) Identification)
20 Kingsbridge Road, Piscataway, New Jersey 08854
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (732) 980-4500
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events
Schering-Plough Corporation has advanced PEG-INTRON A(R), a long-acting
dose formulation of Schering-Plough's INTRON(R) A, into Phase III clinical
trials for chronic myelogenous leukemia.
PEG-INTRON A is in Phase III clinical trials for hepatitis C and malignant
melanoma and is in early phase clinical trials for solid tumors, as well as in
combination with REBETOL (R) for hepatitis C.
Except for the historical information herein, the matters discussed in this
Form 8-K include forward-looking statements that may involve a number of risks
and uncertainties. Actual results may vary significantly based upon a number of
factors which are described in the Company's Form 10-Ks, Form 10-Qs and Form
8-Ks on file with the SEC, including without limitation, risks in obtaining and
maintaining regulatory approval for expanded indications, market acceptance of
an continuing demand for Enzon's products and the impact of competitive products
and pricing.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: December 7, 1998
ENZON, INC.
(Registrant)
By: /s/ Kenneth J. Zuerblis
--------------------------------------
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial Officer (Principal
Financial Officer and Principal
Accounting Officer)
